Cargando…

Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A

When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Sager, Cristian, Burek, Carol, Durán, Victor, Corbetta, Juan Pablo, Weller, Santiago, Juan, Bortagaray, López, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scholarly Research Network 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376763/
https://www.ncbi.nlm.nih.gov/pubmed/22720170
http://dx.doi.org/10.5402/2012/763159
_version_ 1782235864162631680
author Sager, Cristian
Burek, Carol
Durán, Victor
Corbetta, Juan Pablo
Weller, Santiago
Juan, Bortagaray
López, Juan Carlos
author_facet Sager, Cristian
Burek, Carol
Durán, Victor
Corbetta, Juan Pablo
Weller, Santiago
Juan, Bortagaray
López, Juan Carlos
author_sort Sager, Cristian
collection PubMed
description When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse effects. Due to its transitory effect, it is necessary to repeat the injections in order to sustain its therapeutic effect. In these review article we talk about Mechanism of Action, Indications, effects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also, we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients younger than 18 years of age and reports written in English in the past ten years.
format Online
Article
Text
id pubmed-3376763
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher International Scholarly Research Network
record_format MEDLINE/PubMed
spelling pubmed-33767632012-06-20 Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A Sager, Cristian Burek, Carol Durán, Victor Corbetta, Juan Pablo Weller, Santiago Juan, Bortagaray López, Juan Carlos ISRN Urol Review Article When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse effects. Due to its transitory effect, it is necessary to repeat the injections in order to sustain its therapeutic effect. In these review article we talk about Mechanism of Action, Indications, effects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also, we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients younger than 18 years of age and reports written in English in the past ten years. International Scholarly Research Network 2012-06-07 /pmc/articles/PMC3376763/ /pubmed/22720170 http://dx.doi.org/10.5402/2012/763159 Text en Copyright © 2012 Cristian Sager et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Sager, Cristian
Burek, Carol
Durán, Victor
Corbetta, Juan Pablo
Weller, Santiago
Juan, Bortagaray
López, Juan Carlos
Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title_full Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title_fullStr Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title_full_unstemmed Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title_short Pharmacotherapy in Pediatric Neurogenic Bladder Intravesical Botulinum Toxin Type A
title_sort pharmacotherapy in pediatric neurogenic bladder intravesical botulinum toxin type a
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376763/
https://www.ncbi.nlm.nih.gov/pubmed/22720170
http://dx.doi.org/10.5402/2012/763159
work_keys_str_mv AT sagercristian pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT burekcarol pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT duranvictor pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT corbettajuanpablo pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT wellersantiago pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT juanbortagaray pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea
AT lopezjuancarlos pharmacotherapyinpediatricneurogenicbladderintravesicalbotulinumtoxintypea